Custom Criteria for
BlueCross Blue Shield of Rhode Island Commercial

KINERET® (anakinra)

GPI CODING:

66260010002020

DESCRIPTION:

Kineret, an interleukin-1 (IL-1) receptor antagonist, is FDA-approved for the reducing signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease modifying antirheumatic drugs (DMARDs). Kineret may also be used for the treatment of systemic juvenile idiopathic arthritis (sJIA) and adult Still's disease.

APPROVAL DURATION:

Approval is for lifetime

CRITERIA FOR KINERET

I. Diagnosis of moderate to severe rheumatoid arthritis (RA) and meets all of the following:
   A. Patients must be 18 years of age or older
   B. Patient must have moderately to severely active RA
   C. Patient has had an inadequate response to one or more nonbiologic DMARDs, or such therapy is contraindicated or not tolerated:
      1. Auranofin (Ridaura)
      2. Azathioprine (Imuran)
      3. Cyclophosphamide (Cytoxan or Neosar)
      4. Cyclosporine (Neoral or Sandimmune)
      5. Gold sodium thiomalate (Myochrysine)
      6. Hydroxychloroquine (Plaquenil)
      7. Leflunomide (Arava)
      8. Methotrexate
      9. Minocycline (Minocin or Dynacin)
      10. Penicillamine (Cuprimine, Depen)
      11. Sulfasalazine (Azulfidine, Azulfidine EN-tabs)
   D. Patient has had an inadequate response, intolerance, or confirmed adverse event to Enbrel (etanercept), Humira (adalimumab) or Remicade (infliximab) OR
   E. Patient has one of the following clinical reasons to avoid the use of Enbrel, Remicade or Humira
      1. Contraindication to Enbrel, Remicade, and Humira
      2. History of demyelinating disorder
      3. History of congestive heart failure
      4. History of hepatitis B infection
   F. Patient will not use Kineret in combination with a tumor necrosis factor blocking agent or Orencia (abatacept)

II. Diagnosis of sJIA or adult Still's disease and meets all of the following:

A. Patient has active systemic features (eg, fever)
   1. Patient has had an inadequate response to systemic glucocorticoid therapy, or such therapy is contraindicated or not tolerated **AND**
   2. Patient will not use Kineret in combination with a tumor necrosis factor blocking agent or Orencia (abatacept)

OR

B. Patient has moderately to highly active arthritis
   1. Patient has had an inadequate response to methotrexate or such therapy is contraindicated or not tolerated **AND**
   2. Patient has had an inadequate response, intolerance, contraindication, or confirmed adverse event to Enbrel (etanercept), Humira (adalimumab) or Remicade (infliximab) **AND**
   3. Patient will not use Kineret in combination with a tumor necrosis factor blocking agent or Orencia (abatacept)